References
1. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359 (15): 1577–89. DOI: https://doi.org/10.1056/NEJMoa0806470
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352 (9131): 837–53.
3. Defronzo R.A., Mehta R.J., Schnure J.J. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract (1995). 2013; 41 (2): 132–47. DOI: https://doi.org/10.3810/hp.2013.04.1062
4. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366 (9493): 1279–89. DOI: https://doi.org/10.1016/S0140-6736(05)67528-9
5. Sinha B., Ghosal S. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials. Sci Rep. 2020; 10 (1): 15781. DOI: https://doi.org/10.1038/s41598-020-72967-8
6. Yaghi S., Furie K.L., Viscoli C.M., Kamel H., et al.; IRIS Trial Investigators. Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS trial (Insulin Resistance Intervention after Stroke). Circulation. 2018; 137 (5): 455–63. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.030458
7. Nauck M.A., Ellis G.C., Fleck P.R., Wilson C.A., Mekki Q.; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009; 63 (1): 46–55. DOI: https://doi.org/10.1111/j.1742-1241.2008.01933.x
8. Pratley R.E., Fleck P., Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014; 16 (7): 613–21. DOI: https://doi.org/10.1111/dom.12258
9. Del Prato S., Camisasca R., Wilson C., Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014; 16 (12): 1239–46. DOI: https://doi.org/10.1111/dom.12377
10. Pratley R.E. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2009; 10 (3): 503–12. DOI: https://doi.org/10.1517/14656560802694713
11. Shih C.J., Chen H.T., Kuo S.C., Ou S.M., Chen Y.T. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in elderly patients with type 2 diabetes: a nationwide study. J Am Med Dir Assoc. 2016; 17 (1): 59–64. DOI: https://doi.org/10.1016/j.jamda.2015.10.009
12. White W.B., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. Aust J Clin Endocrinol Metab. 2014; 2 (7): 77.
13. Spinar J., Smahelová A. SAVOR-TIMI 53 – Vysledky saxagliptinu a kardiovaskularni vysledky u pacientu s diabetes mellitus 2 typu [SAVOR TIMI 53 – Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus]. Vnitr Lek. 2013; 59 (11): 1003–7. (in Czech)
14. Cornel J.H. Bakris G.L., Stevens S.R., Alvarsson M., Bax W.A., Chuang L.M., et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016; 39 (12): 2304–10.
15. Perkovic V., Toto R., Cooper M.E., Mann J.F.E., Rosenstock J., McGuire D.K., CARMELINA investigators. Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the carmelina randomized trial. Diabetes Care. 2020; 43 (8): 1803–12.
16. Terasaki M., Nagashima M., Nohtomi K., et al. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin’s actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One. 2013; 8 (8): 1–12.
17. Zeng Y., Li C., Guan M., Zheng Z., Li J., Xu W., et al. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc Diabetol. 2014; 13 (1): 1–10.
18. Mita T., Katakami N., Yoshii H., et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care. 2016; 39 (1): 139–48.
19. Langenfeld M.R., Forst T., Hohberg C., et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005; 111 (19): 2525–31.
20. Walker S.R., Komenda P., Khojah S., et al. Dipeptidyl peptidase-4 inhibitors in chronic kidney disease: a systematic review of randomized clinical trials. Nephron. 2017; 136 (2): 85–94.